Analysis of satisfaction with drug therapy for benign prostatic hyperplasia in elderly and senile patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Age is a non-modifiable risk factor for the development of benign prostatic hyperplasia (BPH). The algorithm of drug treatment of BPH is well known. From the perspective of modern patient-oriented medicine, when evaluating the efficiency of treatment, the subjective assessment by the patient, including satisfaction with the therapy, are important. Predictors of patients' dissatisfaction with drug therapy and low adherence to treatment are the persistence of lower urinary tract symptoms, especially nocturia, as well as the presence of erectile dysfunction. It is recommended to integrate the evaluation of treatment satisfaction into routine clinical practice, which will improve the quality of medical care. We have presented a literature review of satisfaction with drug therapy in elderly and senile patients with BPH, according to modern literature. The literature sources for 2018-2023 in the databases Springer, PubMed, eLibrary, Cyberleninca in Russian and English on the subjective assessments by patients of the older age of the treatment of BPH were analyzed.

Full Text

Restricted Access

About the authors

Sergey V. Popov

GBUZ «City Hospital Saint Luka»; FGBVOU VO S.M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation; PHEI «St. Petersburg Medical and Social Institute»

Email: doc.popov@gmail.com
ORCID iD: 0000-0003-2767-7153

Ph.D., MD, professor, Chief of the Saint Petersburg, Head of the Center of Endourology and New Technologies, professor at the Department

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46; Saint Petersburg; Saint Petersburg

Ruslan H. Huseynov

GBUZ «City Hospital Saint Luka»; FGBOU VO Saint-Petersburg State University; PHEI «St. Petersburg Medical and Social Institute»

Email: rusfa@yandex.ru
ORCID iD: 0000-0001-9935-0243

Ph.D., Deputy Director on Scientific work of GBUZ «City Hospital Saint Luka», assistant at the Department of Hospital Surgery

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46; Saint Petersburg; Saint Petersburg

Konstantin V. Sivak

GBUZ «City Hospital Saint Luka»; FGBU Smorodintsev Research Institute of Influenza of the Ministry of Health of Russia

Email: tatianalelyavina@mail.ru
ORCID iD: 0000-0003-4064-5033

Ph.D., MD, leading researcher at the scientific department of GBUZ «City Hospital Saint Luka»

 

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46; Saint Petersburg

Evgeny V. Pomeshkin

GBUZ «City Hospital Saint Luka»

Email: pomeshkin@mail.ru

Ph.D., Head of the Department of Urology

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46

Dauren I. Sengirbaev

GBUZ «City Hospital Saint Luka»; NAO «Kazakh National Medical University named after S.D. Aspendiyarova»

Email: info@lucaclinic.ru
ORCID iD: 0000-0003-1416-7517

researcher

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46; Almaty, Kazakhstan

Vitaly V. Perepelitsa

GBUZ «City Hospital Saint Luka»; PHEI «St. Petersburg Medical and Social Institute»

Email: perepelitsa_vit@mail.ru
ORCID iD: 0000-0002-7656-4473

Ph.D., urologist

 

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46; Saint Petersburg

Nikolai V. Bunenkov

GBUZ «City Hospital Saint Luka»; FGBOU VO Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

Email: info@lucaclinic.ru

researcher

Russian Federation, 194044, St. Petersburg, st. Cast iron, 46; Saint Petersburg

Tatyana A. Lelyavina

FGBU National Medical Research Center named after V.A. Almazov of the Ministry of Health of the Russian Federation; GBUZ «City Hospital Saint Luka»

Author for correspondence.
Email: tatianalelyavina@mail.ru
ORCID iD: 0000-0001-6796-4064

Ph.D., MD, leading researcher at the Research Institute of Microcirculation and Myocardial Metabolism

Russian Federation, Saint Petersburg; 194044, St. Petersburg, st. Cast iron, 46

References

  1. Miernik A., Gratzke C. Current Treatment for Benign Prostatic Hyperplasia. Dtsch Arztebl Int. 2020;117(49):843–854. doi: 10.3238/arztebl.2020.0843
  2. Lewis A.L., Young G.J., Abrams P., Blair P.S., Chapple C., Glazener C.M. et al. Clinical and patient-reported outcome measures in men referred for consideration of surgery to treat lower urinary tract symptoms: baseline results and diagnostic findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). European Urology Focus. 2019;5(3):340-350. doi: 10.1016/j.euf.2019.04.006
  3. Benign prostatic hyperplasia. Clinical recommendations. 2024. Russian (Доброкачественная гиперплазия предстательной железы. Клинические рекомендации. 2024).
  4. Mukhina S.M., Orlova E.V. Patient-reported outcomes: an overview of applications. Real-World Data & Evidence. 2022;2(2):1–7. Russian (Мухина С.М., Орлова Е.В. Исходы, сообщаемые пациентами: обзор направлений применения. Реальная клиническая практика: данные и доказательства. 2022;2(2):1–7). doi: 10.37489/2782-3784-myrwd-12
  5. Koh H.J.W., Whitelock-Wainwright E., Gasevic D., Rankin D., Romero L., Frydenberg M. et al. Quality Indicators in the Clinical Specialty of Urology: A Systematic Review. Eur Urol Focus. 2022: S2405-4569(22)00288-7. doi: 10.1016/j.euf.2022.12.004
  6. Endovitsky A.A., Lyutsko V.V., Khodakova E.A. Patient satisfaction with the quality and accessibility of medical care in the Urology profile provided on an outpatient basis. Modern problems of health care and medical statistics. 2022;5:513–527. Russian (Ендовицкий А.А., Люцко В.В., Ходакова Е.А. Удовлетворенность пациентов качеством и доступностью медицинской помощи по профилю «Урология», оказываемой в амбулаторных условиях. Современные проблемы здравоохранения и медицинской статистики. 2022;5:513–527).
  7. Sze C., Chughtai B., Kaplan S.A. I Can’t Get No Satisfaction: Patient-reported Outcomes After Different Treatment Options for Lower Urinary Tract Symptoms. Eur Urol Focus. 2022;8(2):377–379. doi: 10.1016/j.euf.2022.03.002.
  8. Kim B.S., Kim T.H., Kim K.H., Kim B.H., Ha J.Y., Cho D.H. et al. Patient-reported Goal Achievement after Treating Male Benign Prostatic Hyperplasia with Alpha-adrenergic Antagonist: A 12-week Prospective Multicenter Study. Urol J. 2019;16(4):386–391. doi: 10.22037/uj.v0i0.3784.
  9. Zabkowski T., Saracyn M. Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol. 2018;69(4). doi: 10.26402/jpp.2018.4.14
  10. Lyauk Y.K., Lund T.M., Hooker A.C., Karlsson M.O., Jonker D.M. Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. AAPS J. 2020;22(5):98. doi: 10.1208/s12248-020-00484-7.
  11. Yokoyama O., Ozeki A., Suzuki N., Murakami M. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia. Int J Urol. 2018;25(3):240–245. doi: 10.1111/iju.13487.
  12. Takahashi R., Miyazato M., Nishii H., Sumino Y., Takayama K., Onzuka M. et al. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study). Low Urin Tract Symptoms. 2018;10(1):76–83. doi: 10.1111/luts.12143.
  13. Harrell M.B., Ho K., Te A.E., Kaplan S.A., Chughtai B. An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World J Urol. 2021;39(4):1233–1239. doi: 10.1007/s00345-020-03314-9
  14. Chislett B., Chen D., Perera M.L., Chung E., Bolton D., Qu L.G. 5-alpha reductase inhibitors use in prostatic disease and beyond. Transl Androl Urol. 2023;12(3):487–496. doi: 10.21037/tau-22-690
  15. Couteau N., Duquesne I., Frédéric P., Thiounn N., Timsit M.O., Mejean A. et al. Ejaculations and Benign Prostatic Hyperplasia: An Impossible Compromise? A Comprehensive Review. J Clin Med. 2021;10(24):5788. doi: 10.3390/jcm10245788
  16. Moon H.W., Yang J.H., Choi J.B., Bae W.J., Cho H.J., Hong S.H. et al. Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia. Sci Rep. 2018;8(1):13223. doi: 10.1038/s41598-018-31617-w.
  17. Romano C.D., Lewis S., Barrett A., Andersson F.L., Williams V., Ancoli-Israel S. et al. Development of the Nocturia Sleep Quality Scale: a patient-reported outcome measure of sleep impact related to nocturia. Sleep Med. 2019;59:101–106. doi: 10.1016/j.sleep.2019.02.006.
  18. Malde S., Patel A., Martínez-Piñeiro L., de la Taille A., Bjartell A., Tubaro A. et al. Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. Eur Urol Focus. 2021;7(1):178–185. doi: 10.1016/j.euf.2019.07.003
  19. Ahn S.T., Lee D.H., Jeong H.G., Kim J.W., Oh M.M., Park H.S. et al. Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction. Investig Clin Urol. 2020;61(1):81–87. doi: 10.4111/icu.2020.61.1.81.
  20. Soliman M.G., Al-Ghadeer M.R., Al-Shabaan H.R., Al-Hamrani A.H., AlGhadeer H.A. Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia. Urol Ann. 2023;15(1):43–47. doi: 10.4103/ua.ua_143_21.
  21. Peshekhonov K.S., Shpilenia E.S., Burlaka O.O. Significance of the pharmacoeconomic approach in the choice of treatment of hyperplasia of the prostate. Urologicheskie vedomosti. 2019;9(4):59–72. Russian (Пешехонов К.С., Шпиленя Е.С., Бурлака О.О. Значимость фармакоэкономического подхода при выборе лечения гиперплазии предстательной железы. Урологические ведомости. 2019;9(4):59–72). doi: 10.17816/uroved9459-72.
  22. Borisov V.V. Combination of a1-blockers and phosphodiesterase type 5 inhibitor in patients with benign prostatic hyperplasia and erectile dysfunction: results of observatory prospective multicenter study. Urologiia. 2020;3:50–55. Russian (Борисов В.В. Комбинированная терапия а1-адреноблокатором и ингибитором фосфодиэстеразы 5-го типа пациентов с доброкачественной гиперплазией предстательной железы и эректильной дисфункцией: результаты наблюдательного проспективного мультицентрового исследования. Урология. 2020;3:50–55). doi: 10.18565/urology.2020.3.50-55
  23. Rees J., Foley S., Huang M., Arias J.R., Skoumal R., Walters C. et al. De Wachter. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Experimental and clinical urology 2019;(3):134–143. Russian (Rees J., Foley S., Huang M., Arias J.R., Skoumal R., Walters C. и др. Повышение качества жизни мужчин с симптомами нижних мочевых путей при применении Везомни в рутинной клинической практике в Европе. Экспериментальная и клиническая урология. 2019;(3):134–143). doi: 10.29188/2222-8543-2019-11-3-134-143
  24. Yamanishi T., Kaga K., Sakata K., Yokoyama T., Kageyama S., Fuse M. et al. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn. 2020;39(2):804–812. doi: 10.1002/nau.24285
  25. Roehrborn C.G., Rukstalis D.B. Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia. Eur Urol Focus. 2022;8(1):217–227. doi: 10.1016/j.euf.2020.12.013.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media